You are here
Home > Healthcare > Here’s One Reason Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Stock is Losing Almost 6% Today

Here’s One Reason Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Stock is Losing Almost 6% Today

On Thursday, Shares of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) lost -5.40% to $0.3699, soon after a clinical-stage biopharmaceutical company stated financial results for the fourth quarter and full year ended December 31, 2015 and offered a planned update and review of recent business highlights.

During the day, the lowest price at which share traded is $0.34 and hit the highest price at $0.42. The stock’s institutional ownership stands at 80%.

Fourth Quarter and Year-End 2015 Financial Results:

Revenue: Revenue was $0.60M for the three months ended December 31, 2015, contrast to $0.40 million for the same period in 2014. Revenue was $1.0 million for the twelve months ended December 31, 2015, contrast to $2.2 million for the same period in 2014.

R&D Expenses: Research and development expenses were $8.1 million for the three months ended December 31, 2015, contrast to $5.3 million for the same period in 2014. This increase was mainly because of higher EBI-031 related development expenses partially offset by decreases in isunakinra related development expenses. Research and development expenses were $26.3 million for the twelve months ended December 31, 2015, contrast to $26.7 million for the same period in 2014.

G&A Expenses: General and administrative expenses were $2.30 million for the three months ended December 31, 2015, contrast to $2.20 million for the same period in 2014. General and administrative expenses were $9.90 million for the twelve months ended December 31, 2015, contrast to $8.50 million for the same period in 2014.

Net Loss: Net loss applicable to common stockholders was $10.30 million, or $0.53 per share, for the three months ended December 31, 2015, contrast to net loss applicable to common stockholders of $8.10 million, or $0.49 per share, for the same period in 2014. Net loss applicable to common stockholders was $33.50 million, or $1.76 per share, for the twelve months ended December 31, 2015, contrast to net loss applicable to common stockholders of $34.70 million, or $2.370 per share, for the same period in 2014.

Cash and Cash Equivalents: Cash and cash equivalents were $36.10 million as of December 31, 2015. The company believes that its current cash and cash equivalents, after giving effect to the $14.90 million prepayment to Silicon Valley Bank, will be sufficient to fund its operating expenses into the fourth quarter of 2016.

Eleven Biotherapeutics has market value of $7.05M while its EPS was booked as $-1.71 in the last 12 months. The stock has 19.59M shares outstanding.

FacebookTwitter
Tags :
Top